-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The cumulative amount of the reporting entity's undistributed earnings or deficit.
-
Summary
-
ARS Pharmaceuticals, Inc. quarterly Retained Earnings (Accumulated Deficit) history and growth rate from Q4 2020 to Q3 2024.
- ARS Pharmaceuticals, Inc. Retained Earnings (Accumulated Deficit) for the quarter ending September 30, 2024 was -$173M, a 39.6% decline year-over-year.
Retained Earnings (Accumulated Deficit), Quarterly (USD)
Retained Earnings (Accumulated Deficit), YoY Quarterly Growth (%)